nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—Nateglinide—Bortezomib—hematologic cancer	0.153	0.258	CrCrCtD
Dextroamphetamine—Aspartame—Bortezomib—hematologic cancer	0.146	0.245	CrCrCtD
Dextroamphetamine—Lacosamide—Bortezomib—hematologic cancer	0.146	0.245	CrCrCtD
Dextroamphetamine—Phenacemide—Vorinostat—hematologic cancer	0.116	0.195	CrCrCtD
Dextroamphetamine—L-Phenylalanine—Melphalan—hematologic cancer	0.0341	0.0574	CrCrCtD
Dextroamphetamine—CYP2D6—Lomustine—hematologic cancer	0.0243	0.189	CbGbCtD
Dextroamphetamine—CYP2D6—Idarubicin—hematologic cancer	0.0217	0.168	CbGbCtD
Dextroamphetamine—CYP2D6—Hydroxyurea—hematologic cancer	0.0184	0.143	CbGbCtD
Dextroamphetamine—CYP2D6—Bortezomib—hematologic cancer	0.016	0.124	CbGbCtD
Dextroamphetamine—CYP2D6—Imatinib—hematologic cancer	0.0118	0.0912	CbGbCtD
Dextroamphetamine—CYP2D6—Nilotinib—hematologic cancer	0.0107	0.0829	CbGbCtD
Dextroamphetamine—CYP2D6—Vinorelbine—hematologic cancer	0.0106	0.0822	CbGbCtD
Dextroamphetamine—CYP2D6—Vinblastine—hematologic cancer	0.00653	0.0506	CbGbCtD
Dextroamphetamine—CYP2D6—Dexamethasone—hematologic cancer	0.00483	0.0375	CbGbCtD
Dextroamphetamine—CYP2D6—Doxorubicin—hematologic cancer	0.00401	0.0311	CbGbCtD
Dextroamphetamine—TAAR1—lung—hematologic cancer	0.00194	0.178	CbGeAlD
Dextroamphetamine—SLC18A2—hematopoietic system—hematologic cancer	0.00113	0.104	CbGeAlD
Dextroamphetamine—SLC6A3—hematopoietic system—hematologic cancer	0.000858	0.0789	CbGeAlD
Dextroamphetamine—SLC18A2—blood—hematologic cancer	0.000752	0.0691	CbGeAlD
Dextroamphetamine—SLC18A2—lung—hematologic cancer	0.000659	0.0606	CbGeAlD
Dextroamphetamine—ADRA1A—hematopoietic system—hematologic cancer	0.000644	0.0592	CbGeAlD
Dextroamphetamine—SLC18A2—testis—hematologic cancer	0.000622	0.0572	CbGeAlD
Dextroamphetamine—SLC6A2—gonad—hematologic cancer	0.000527	0.0484	CbGeAlD
Dextroamphetamine—SLC6A3—lung—hematologic cancer	0.000499	0.0458	CbGeAlD
Dextroamphetamine—Pseudoephedrine—IL2—hematologic cancer	0.000475	0.344	CrCbGaD
Dextroamphetamine—SLC6A3—testis—hematologic cancer	0.00047	0.0432	CbGeAlD
Dextroamphetamine—SLC18A2—lymph node—hematologic cancer	0.000451	0.0414	CbGeAlD
Dextroamphetamine—ADRA1A—blood—hematologic cancer	0.000427	0.0392	CbGeAlD
Dextroamphetamine—SLC6A2—lung—hematologic cancer	0.000402	0.037	CbGeAlD
Dextroamphetamine—SLC6A2—testis—hematologic cancer	0.00038	0.0349	CbGeAlD
Dextroamphetamine—CYP2D6—hematopoietic system—hematologic cancer	0.000379	0.0349	CbGeAlD
Dextroamphetamine—Phenformin—SLC22A1—hematologic cancer	0.000343	0.249	CrCbGaD
Dextroamphetamine—Lacosamide—CA9—hematologic cancer	0.000279	0.202	CrCbGaD
Dextroamphetamine—SLC6A2—lymph node—hematologic cancer	0.000275	0.0253	CbGeAlD
Dextroamphetamine—CYP2D6—blood—hematologic cancer	0.000251	0.0231	CbGeAlD
Dextroamphetamine—CYP2D6—testis—hematologic cancer	0.000208	0.0191	CbGeAlD
Dextroamphetamine—Pseudoephedrine—TNF—hematologic cancer	0.00016	0.116	CrCbGaD
Dextroamphetamine—Selegiline—ABCB1—hematologic cancer	6.32e-05	0.0458	CrCbGaD
Dextroamphetamine—Nateglinide—ALB—hematologic cancer	5.92e-05	0.0429	CrCbGaD
Dextroamphetamine—Insomnia—Triamcinolone—hematologic cancer	5.88e-05	0.000287	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Etoposide—hematologic cancer	5.86e-05	0.000286	CcSEcCtD
Dextroamphetamine—Infection—Dexamethasone—hematologic cancer	5.86e-05	0.000286	CcSEcCtD
Dextroamphetamine—Infection—Betamethasone—hematologic cancer	5.86e-05	0.000286	CcSEcCtD
Dextroamphetamine—Dizziness—Vincristine—hematologic cancer	5.85e-05	0.000285	CcSEcCtD
Dextroamphetamine—Rash—Carmustine—hematologic cancer	5.84e-05	0.000285	CcSEcCtD
Dextroamphetamine—Dermatitis—Carmustine—hematologic cancer	5.84e-05	0.000285	CcSEcCtD
Dextroamphetamine—Vomiting—Alitretinoin—hematologic cancer	5.84e-05	0.000285	CcSEcCtD
Dextroamphetamine—Headache—Carmustine—hematologic cancer	5.8e-05	0.000283	CcSEcCtD
Dextroamphetamine—Dyspnoea—Triamcinolone—hematologic cancer	5.79e-05	0.000283	CcSEcCtD
Dextroamphetamine—Rash—Alitretinoin—hematologic cancer	5.79e-05	0.000282	CcSEcCtD
Dextroamphetamine—Agitation—Prednisone—hematologic cancer	5.78e-05	0.000282	CcSEcCtD
Dextroamphetamine—Dermatitis—Alitretinoin—hematologic cancer	5.78e-05	0.000282	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Doxorubicin—hematologic cancer	5.78e-05	0.000282	CcSEcCtD
Dextroamphetamine—Vomiting—Ifosfamide—hematologic cancer	5.77e-05	0.000281	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Cisplatin—hematologic cancer	5.76e-05	0.000281	CcSEcCtD
Dextroamphetamine—Tachycardia—Betamethasone—hematologic cancer	5.75e-05	0.000281	CcSEcCtD
Dextroamphetamine—Tachycardia—Dexamethasone—hematologic cancer	5.75e-05	0.000281	CcSEcCtD
Dextroamphetamine—Headache—Alitretinoin—hematologic cancer	5.75e-05	0.000281	CcSEcCtD
Dextroamphetamine—Angioedema—Prednisone—hematologic cancer	5.75e-05	0.000281	CcSEcCtD
Dextroamphetamine—Diarrhoea—Gemcitabine—hematologic cancer	5.74e-05	0.00028	CcSEcCtD
Dextroamphetamine—Nausea—Thalidomide—hematologic cancer	5.73e-05	0.00028	CcSEcCtD
Dextroamphetamine—Dyspepsia—Triamcinolone—hematologic cancer	5.72e-05	0.000279	CcSEcCtD
Dextroamphetamine—Rash—Ifosfamide—hematologic cancer	5.72e-05	0.000279	CcSEcCtD
Dextroamphetamine—Dermatitis—Ifosfamide—hematologic cancer	5.71e-05	0.000279	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Methotrexate—hematologic cancer	5.71e-05	0.000279	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Dexamethasone—hematologic cancer	5.7e-05	0.000278	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Betamethasone—hematologic cancer	5.7e-05	0.000278	CcSEcCtD
Dextroamphetamine—Dizziness—Irinotecan—hematologic cancer	5.7e-05	0.000278	CcSEcCtD
Dextroamphetamine—Urticaria—Etoposide—hematologic cancer	5.69e-05	0.000278	CcSEcCtD
Dextroamphetamine—Abdominal pain—Etoposide—hematologic cancer	5.66e-05	0.000276	CcSEcCtD
Dextroamphetamine—Body temperature increased—Etoposide—hematologic cancer	5.66e-05	0.000276	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Doxorubicin—hematologic cancer	5.66e-05	0.000276	CcSEcCtD
Dextroamphetamine—Vomiting—Vincristine—hematologic cancer	5.62e-05	0.000274	CcSEcCtD
Dextroamphetamine—Anorexia—Dexamethasone—hematologic cancer	5.62e-05	0.000274	CcSEcCtD
Dextroamphetamine—Anorexia—Betamethasone—hematologic cancer	5.62e-05	0.000274	CcSEcCtD
Dextroamphetamine—Urticaria—Prednisolone—hematologic cancer	5.61e-05	0.000274	CcSEcCtD
Dextroamphetamine—Asthenia—Cisplatin—hematologic cancer	5.61e-05	0.000274	CcSEcCtD
Dextroamphetamine—Fatigue—Triamcinolone—hematologic cancer	5.6e-05	0.000273	CcSEcCtD
Dextroamphetamine—Sweating—Doxorubicin—hematologic cancer	5.59e-05	0.000273	CcSEcCtD
Dextroamphetamine—Rash—Vincristine—hematologic cancer	5.58e-05	0.000272	CcSEcCtD
Dextroamphetamine—Dermatitis—Vincristine—hematologic cancer	5.57e-05	0.000272	CcSEcCtD
Dextroamphetamine—Headache—Vincristine—hematologic cancer	5.54e-05	0.00027	CcSEcCtD
Dextroamphetamine—Nausea—Carmustine—hematologic cancer	5.5e-05	0.000269	CcSEcCtD
Dextroamphetamine—Vomiting—Mitoxantrone—hematologic cancer	5.48e-05	0.000267	CcSEcCtD
Dextroamphetamine—Vomiting—Irinotecan—hematologic cancer	5.48e-05	0.000267	CcSEcCtD
Dextroamphetamine—Nausea—Alitretinoin—hematologic cancer	5.45e-05	0.000266	CcSEcCtD
Dextroamphetamine—Convulsion—Prednisone—hematologic cancer	5.45e-05	0.000266	CcSEcCtD
Dextroamphetamine—Hypertension—Prednisone—hematologic cancer	5.43e-05	0.000265	CcSEcCtD
Dextroamphetamine—Rash—Irinotecan—hematologic cancer	5.43e-05	0.000265	CcSEcCtD
Dextroamphetamine—Rash—Mitoxantrone—hematologic cancer	5.43e-05	0.000265	CcSEcCtD
Dextroamphetamine—Dermatitis—Irinotecan—hematologic cancer	5.43e-05	0.000265	CcSEcCtD
Dextroamphetamine—Dermatitis—Mitoxantrone—hematologic cancer	5.43e-05	0.000265	CcSEcCtD
Dextroamphetamine—Headache—Irinotecan—hematologic cancer	5.4e-05	0.000263	CcSEcCtD
Dextroamphetamine—Headache—Mitoxantrone—hematologic cancer	5.4e-05	0.000263	CcSEcCtD
Dextroamphetamine—Nausea—Ifosfamide—hematologic cancer	5.39e-05	0.000263	CcSEcCtD
Dextroamphetamine—Diarrhoea—Cisplatin—hematologic cancer	5.35e-05	0.000261	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Epirubicin—hematologic cancer	5.34e-05	0.000261	CcSEcCtD
Dextroamphetamine—Anxiety—Prednisone—hematologic cancer	5.34e-05	0.00026	CcSEcCtD
Dextroamphetamine—Vomiting—Gemcitabine—hematologic cancer	5.33e-05	0.00026	CcSEcCtD
Dextroamphetamine—Insomnia—Dexamethasone—hematologic cancer	5.33e-05	0.00026	CcSEcCtD
Dextroamphetamine—Insomnia—Betamethasone—hematologic cancer	5.33e-05	0.00026	CcSEcCtD
Dextroamphetamine—Rash—Gemcitabine—hematologic cancer	5.29e-05	0.000258	CcSEcCtD
Dextroamphetamine—Dermatitis—Gemcitabine—hematologic cancer	5.29e-05	0.000258	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Etoposide—hematologic cancer	5.28e-05	0.000258	CcSEcCtD
Dextroamphetamine—Headache—Gemcitabine—hematologic cancer	5.26e-05	0.000256	CcSEcCtD
Dextroamphetamine—Nausea—Vincristine—hematologic cancer	5.25e-05	0.000256	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Prednisolone—hematologic cancer	5.21e-05	0.000254	CcSEcCtD
Dextroamphetamine—Dyspepsia—Betamethasone—hematologic cancer	5.19e-05	0.000253	CcSEcCtD
Dextroamphetamine—Dyspepsia—Dexamethasone—hematologic cancer	5.19e-05	0.000253	CcSEcCtD
Dextroamphetamine—Urticaria—Triamcinolone—hematologic cancer	5.16e-05	0.000252	CcSEcCtD
Dextroamphetamine—Asthenia—Etoposide—hematologic cancer	5.14e-05	0.000251	CcSEcCtD
Dextroamphetamine—Body temperature increased—Triamcinolone—hematologic cancer	5.14e-05	0.000251	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Prednisone—hematologic cancer	5.13e-05	0.000251	CcSEcCtD
Dextroamphetamine—Decreased appetite—Betamethasone—hematologic cancer	5.13e-05	0.00025	CcSEcCtD
Dextroamphetamine—Decreased appetite—Dexamethasone—hematologic cancer	5.13e-05	0.00025	CcSEcCtD
Dextroamphetamine—Nausea—Mitoxantrone—hematologic cancer	5.12e-05	0.00025	CcSEcCtD
Dextroamphetamine—Nausea—Irinotecan—hematologic cancer	5.12e-05	0.00025	CcSEcCtD
Dextroamphetamine—Infection—Prednisone—hematologic cancer	5.1e-05	0.000249	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Betamethasone—hematologic cancer	5.09e-05	0.000248	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	5.09e-05	0.000248	CcSEcCtD
Dextroamphetamine—Fatigue—Dexamethasone—hematologic cancer	5.08e-05	0.000248	CcSEcCtD
Dextroamphetamine—Fatigue—Betamethasone—hematologic cancer	5.08e-05	0.000248	CcSEcCtD
Dextroamphetamine—Tachycardia—Prednisone—hematologic cancer	5.01e-05	0.000245	CcSEcCtD
Dextroamphetamine—Nausea—Gemcitabine—hematologic cancer	4.98e-05	0.000243	CcSEcCtD
Dextroamphetamine—Vomiting—Cisplatin—hematologic cancer	4.97e-05	0.000243	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Prednisone—hematologic cancer	4.96e-05	0.000242	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Doxorubicin—hematologic cancer	4.95e-05	0.000241	CcSEcCtD
Dextroamphetamine—Rash—Cisplatin—hematologic cancer	4.93e-05	0.000241	CcSEcCtD
Dextroamphetamine—Dermatitis—Cisplatin—hematologic cancer	4.93e-05	0.00024	CcSEcCtD
Dextroamphetamine—Diarrhoea—Etoposide—hematologic cancer	4.9e-05	0.000239	CcSEcCtD
Dextroamphetamine—Anorexia—Prednisone—hematologic cancer	4.89e-05	0.000239	CcSEcCtD
Dextroamphetamine—Tension—Epirubicin—hematologic cancer	4.83e-05	0.000236	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.82e-05	0.000235	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Betamethasone—hematologic cancer	4.82e-05	0.000235	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Triamcinolone—hematologic cancer	4.79e-05	0.000234	CcSEcCtD
Dextroamphetamine—Nervousness—Epirubicin—hematologic cancer	4.78e-05	0.000233	CcSEcCtD
Dextroamphetamine—Dizziness—Etoposide—hematologic cancer	4.74e-05	0.000231	CcSEcCtD
Dextroamphetamine—Urticaria—Dexamethasone—hematologic cancer	4.68e-05	0.000229	CcSEcCtD
Dextroamphetamine—Urticaria—Betamethasone—hematologic cancer	4.68e-05	0.000229	CcSEcCtD
Dextroamphetamine—Dizziness—Prednisolone—hematologic cancer	4.67e-05	0.000228	CcSEcCtD
Dextroamphetamine—Asthenia—Triamcinolone—hematologic cancer	4.66e-05	0.000227	CcSEcCtD
Dextroamphetamine—Body temperature increased—Betamethasone—hematologic cancer	4.66e-05	0.000227	CcSEcCtD
Dextroamphetamine—Abdominal pain—Betamethasone—hematologic cancer	4.66e-05	0.000227	CcSEcCtD
Dextroamphetamine—Abdominal pain—Dexamethasone—hematologic cancer	4.66e-05	0.000227	CcSEcCtD
Dextroamphetamine—Body temperature increased—Dexamethasone—hematologic cancer	4.66e-05	0.000227	CcSEcCtD
Dextroamphetamine—Nausea—Cisplatin—hematologic cancer	4.65e-05	0.000227	CcSEcCtD
Dextroamphetamine—Insomnia—Prednisone—hematologic cancer	4.64e-05	0.000227	CcSEcCtD
Dextroamphetamine—Convulsion—Methotrexate—hematologic cancer	4.56e-05	0.000222	CcSEcCtD
Dextroamphetamine—Vomiting—Etoposide—hematologic cancer	4.56e-05	0.000222	CcSEcCtD
Dextroamphetamine—Agitation—Epirubicin—hematologic cancer	4.52e-05	0.000221	CcSEcCtD
Dextroamphetamine—Dyspepsia—Prednisone—hematologic cancer	4.52e-05	0.000221	CcSEcCtD
Dextroamphetamine—Rash—Etoposide—hematologic cancer	4.52e-05	0.00022	CcSEcCtD
Dextroamphetamine—Dermatitis—Etoposide—hematologic cancer	4.51e-05	0.00022	CcSEcCtD
Dextroamphetamine—Headache—Etoposide—hematologic cancer	4.49e-05	0.000219	CcSEcCtD
Dextroamphetamine—Chest pain—Methotrexate—hematologic cancer	4.48e-05	0.000218	CcSEcCtD
Dextroamphetamine—Tension—Doxorubicin—hematologic cancer	4.47e-05	0.000218	CcSEcCtD
Dextroamphetamine—Decreased appetite—Prednisone—hematologic cancer	4.46e-05	0.000218	CcSEcCtD
Dextroamphetamine—Rash—Prednisolone—hematologic cancer	4.46e-05	0.000217	CcSEcCtD
Dextroamphetamine—Dermatitis—Prednisolone—hematologic cancer	4.45e-05	0.000217	CcSEcCtD
Dextroamphetamine—Fatigue—Prednisone—hematologic cancer	4.43e-05	0.000216	CcSEcCtD
Dextroamphetamine—Headache—Prednisolone—hematologic cancer	4.43e-05	0.000216	CcSEcCtD
Dextroamphetamine—Nervousness—Doxorubicin—hematologic cancer	4.42e-05	0.000216	CcSEcCtD
Dextroamphetamine—Constipation—Prednisone—hematologic cancer	4.39e-05	0.000214	CcSEcCtD
Dextroamphetamine—Palpitations—Epirubicin—hematologic cancer	4.35e-05	0.000212	CcSEcCtD
Dextroamphetamine—Dizziness—Triamcinolone—hematologic cancer	4.3e-05	0.00021	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Methotrexate—hematologic cancer	4.29e-05	0.000209	CcSEcCtD
Dextroamphetamine—Convulsion—Epirubicin—hematologic cancer	4.26e-05	0.000208	CcSEcCtD
Dextroamphetamine—Infection—Methotrexate—hematologic cancer	4.26e-05	0.000208	CcSEcCtD
Dextroamphetamine—Nausea—Etoposide—hematologic cancer	4.26e-05	0.000208	CcSEcCtD
Dextroamphetamine—Hypertension—Epirubicin—hematologic cancer	4.25e-05	0.000207	CcSEcCtD
Dextroamphetamine—Asthenia—Dexamethasone—hematologic cancer	4.23e-05	0.000206	CcSEcCtD
Dextroamphetamine—Asthenia—Betamethasone—hematologic cancer	4.23e-05	0.000206	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Prednisone—hematologic cancer	4.2e-05	0.000205	CcSEcCtD
Dextroamphetamine—Nausea—Prednisolone—hematologic cancer	4.2e-05	0.000205	CcSEcCtD
Dextroamphetamine—Chest pain—Epirubicin—hematologic cancer	4.19e-05	0.000204	CcSEcCtD
Dextroamphetamine—Agitation—Doxorubicin—hematologic cancer	4.18e-05	0.000204	CcSEcCtD
Dextroamphetamine—Anxiety—Epirubicin—hematologic cancer	4.17e-05	0.000204	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Methotrexate—hematologic cancer	4.15e-05	0.000202	CcSEcCtD
Dextroamphetamine—Vomiting—Triamcinolone—hematologic cancer	4.13e-05	0.000202	CcSEcCtD
Dextroamphetamine—Rash—Triamcinolone—hematologic cancer	4.1e-05	0.0002	CcSEcCtD
Dextroamphetamine—Dry mouth—Epirubicin—hematologic cancer	4.1e-05	0.0002	CcSEcCtD
Dextroamphetamine—Dermatitis—Triamcinolone—hematologic cancer	4.09e-05	0.0002	CcSEcCtD
Dextroamphetamine—Anorexia—Methotrexate—hematologic cancer	4.09e-05	0.0002	CcSEcCtD
Dextroamphetamine—Urticaria—Prednisone—hematologic cancer	4.08e-05	0.000199	CcSEcCtD
Dextroamphetamine—Headache—Triamcinolone—hematologic cancer	4.07e-05	0.000199	CcSEcCtD
Dextroamphetamine—Body temperature increased—Prednisone—hematologic cancer	4.06e-05	0.000198	CcSEcCtD
Dextroamphetamine—Abdominal pain—Prednisone—hematologic cancer	4.06e-05	0.000198	CcSEcCtD
Dextroamphetamine—Diarrhoea—Dexamethasone—hematologic cancer	4.03e-05	0.000197	CcSEcCtD
Dextroamphetamine—Diarrhoea—Betamethasone—hematologic cancer	4.03e-05	0.000197	CcSEcCtD
Dextroamphetamine—Palpitations—Doxorubicin—hematologic cancer	4.02e-05	0.000196	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Epirubicin—hematologic cancer	4.02e-05	0.000196	CcSEcCtD
Dextroamphetamine—Infection—Epirubicin—hematologic cancer	3.99e-05	0.000195	CcSEcCtD
Dextroamphetamine—Convulsion—Doxorubicin—hematologic cancer	3.94e-05	0.000192	CcSEcCtD
Dextroamphetamine—Hypertension—Doxorubicin—hematologic cancer	3.93e-05	0.000192	CcSEcCtD
Dextroamphetamine—Tachycardia—Epirubicin—hematologic cancer	3.92e-05	0.000191	CcSEcCtD
Dextroamphetamine—Dizziness—Dexamethasone—hematologic cancer	3.9e-05	0.00019	CcSEcCtD
Dextroamphetamine—Dizziness—Betamethasone—hematologic cancer	3.9e-05	0.00019	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Epirubicin—hematologic cancer	3.88e-05	0.000189	CcSEcCtD
Dextroamphetamine—Insomnia—Methotrexate—hematologic cancer	3.88e-05	0.000189	CcSEcCtD
Dextroamphetamine—Chest pain—Doxorubicin—hematologic cancer	3.88e-05	0.000189	CcSEcCtD
Dextroamphetamine—Anxiety—Doxorubicin—hematologic cancer	3.86e-05	0.000188	CcSEcCtD
Dextroamphetamine—Nausea—Triamcinolone—hematologic cancer	3.86e-05	0.000188	CcSEcCtD
Dextroamphetamine—Anorexia—Epirubicin—hematologic cancer	3.83e-05	0.000187	CcSEcCtD
Dextroamphetamine—Dyspnoea—Methotrexate—hematologic cancer	3.83e-05	0.000187	CcSEcCtD
Dextroamphetamine—Somnolence—Methotrexate—hematologic cancer	3.82e-05	0.000186	CcSEcCtD
Dextroamphetamine—Dry mouth—Doxorubicin—hematologic cancer	3.79e-05	0.000185	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Prednisone—hematologic cancer	3.78e-05	0.000185	CcSEcCtD
Dextroamphetamine—Dyspepsia—Methotrexate—hematologic cancer	3.78e-05	0.000184	CcSEcCtD
Dextroamphetamine—Vomiting—Dexamethasone—hematologic cancer	3.75e-05	0.000183	CcSEcCtD
Dextroamphetamine—Vomiting—Betamethasone—hematologic cancer	3.75e-05	0.000183	CcSEcCtD
Dextroamphetamine—Decreased appetite—Methotrexate—hematologic cancer	3.73e-05	0.000182	CcSEcCtD
Dextroamphetamine—Rash—Dexamethasone—hematologic cancer	3.72e-05	0.000181	CcSEcCtD
Dextroamphetamine—Rash—Betamethasone—hematologic cancer	3.72e-05	0.000181	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Doxorubicin—hematologic cancer	3.72e-05	0.000181	CcSEcCtD
Dextroamphetamine—Dermatitis—Betamethasone—hematologic cancer	3.71e-05	0.000181	CcSEcCtD
Dextroamphetamine—Dermatitis—Dexamethasone—hematologic cancer	3.71e-05	0.000181	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.7e-05	0.000181	CcSEcCtD
Dextroamphetamine—Fatigue—Methotrexate—hematologic cancer	3.7e-05	0.000181	CcSEcCtD
Dextroamphetamine—Headache—Betamethasone—hematologic cancer	3.69e-05	0.00018	CcSEcCtD
Dextroamphetamine—Headache—Dexamethasone—hematologic cancer	3.69e-05	0.00018	CcSEcCtD
Dextroamphetamine—Infection—Doxorubicin—hematologic cancer	3.69e-05	0.00018	CcSEcCtD
Dextroamphetamine—Asthenia—Prednisone—hematologic cancer	3.68e-05	0.00018	CcSEcCtD
Dextroamphetamine—Insomnia—Epirubicin—hematologic cancer	3.63e-05	0.000177	CcSEcCtD
Dextroamphetamine—Tachycardia—Doxorubicin—hematologic cancer	3.63e-05	0.000177	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Doxorubicin—hematologic cancer	3.59e-05	0.000175	CcSEcCtD
Dextroamphetamine—Dyspnoea—Epirubicin—hematologic cancer	3.58e-05	0.000175	CcSEcCtD
Dextroamphetamine—Somnolence—Epirubicin—hematologic cancer	3.57e-05	0.000174	CcSEcCtD
Dextroamphetamine—Anorexia—Doxorubicin—hematologic cancer	3.54e-05	0.000173	CcSEcCtD
Dextroamphetamine—Dyspepsia—Epirubicin—hematologic cancer	3.54e-05	0.000172	CcSEcCtD
Dextroamphetamine—Diarrhoea—Prednisone—hematologic cancer	3.51e-05	0.000171	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Methotrexate—hematologic cancer	3.51e-05	0.000171	CcSEcCtD
Dextroamphetamine—Nausea—Dexamethasone—hematologic cancer	3.5e-05	0.000171	CcSEcCtD
Dextroamphetamine—Nausea—Betamethasone—hematologic cancer	3.5e-05	0.000171	CcSEcCtD
Dextroamphetamine—Decreased appetite—Epirubicin—hematologic cancer	3.49e-05	0.00017	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.47e-05	0.000169	CcSEcCtD
Dextroamphetamine—Fatigue—Epirubicin—hematologic cancer	3.46e-05	0.000169	CcSEcCtD
Dextroamphetamine—Constipation—Epirubicin—hematologic cancer	3.43e-05	0.000168	CcSEcCtD
Dextroamphetamine—Urticaria—Methotrexate—hematologic cancer	3.41e-05	0.000166	CcSEcCtD
Dextroamphetamine—Dizziness—Prednisone—hematologic cancer	3.4e-05	0.000166	CcSEcCtD
Dextroamphetamine—Body temperature increased—Methotrexate—hematologic cancer	3.39e-05	0.000166	CcSEcCtD
Dextroamphetamine—Abdominal pain—Methotrexate—hematologic cancer	3.39e-05	0.000166	CcSEcCtD
Dextroamphetamine—Insomnia—Doxorubicin—hematologic cancer	3.36e-05	0.000164	CcSEcCtD
Dextroamphetamine—Dyspnoea—Doxorubicin—hematologic cancer	3.31e-05	0.000162	CcSEcCtD
Dextroamphetamine—Somnolence—Doxorubicin—hematologic cancer	3.3e-05	0.000161	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Epirubicin—hematologic cancer	3.28e-05	0.00016	CcSEcCtD
Dextroamphetamine—Dyspepsia—Doxorubicin—hematologic cancer	3.27e-05	0.00016	CcSEcCtD
Dextroamphetamine—Vomiting—Prednisone—hematologic cancer	3.26e-05	0.000159	CcSEcCtD
Dextroamphetamine—Rash—Prednisone—hematologic cancer	3.24e-05	0.000158	CcSEcCtD
Dextroamphetamine—Dermatitis—Prednisone—hematologic cancer	3.23e-05	0.000158	CcSEcCtD
Dextroamphetamine—Decreased appetite—Doxorubicin—hematologic cancer	3.23e-05	0.000158	CcSEcCtD
Dextroamphetamine—Headache—Prednisone—hematologic cancer	3.22e-05	0.000157	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.21e-05	0.000157	CcSEcCtD
Dextroamphetamine—Fatigue—Doxorubicin—hematologic cancer	3.2e-05	0.000156	CcSEcCtD
Dextroamphetamine—Urticaria—Epirubicin—hematologic cancer	3.19e-05	0.000156	CcSEcCtD
Dextroamphetamine—Constipation—Doxorubicin—hematologic cancer	3.18e-05	0.000155	CcSEcCtD
Dextroamphetamine—Abdominal pain—Epirubicin—hematologic cancer	3.17e-05	0.000155	CcSEcCtD
Dextroamphetamine—Body temperature increased—Epirubicin—hematologic cancer	3.17e-05	0.000155	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Methotrexate—hematologic cancer	3.16e-05	0.000154	CcSEcCtD
Dextroamphetamine—Asthenia—Methotrexate—hematologic cancer	3.08e-05	0.00015	CcSEcCtD
Dextroamphetamine—Nausea—Prednisone—hematologic cancer	3.05e-05	0.000149	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.04e-05	0.000148	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Epirubicin—hematologic cancer	2.96e-05	0.000144	CcSEcCtD
Dextroamphetamine—Urticaria—Doxorubicin—hematologic cancer	2.95e-05	0.000144	CcSEcCtD
Dextroamphetamine—Abdominal pain—Doxorubicin—hematologic cancer	2.94e-05	0.000143	CcSEcCtD
Dextroamphetamine—Body temperature increased—Doxorubicin—hematologic cancer	2.94e-05	0.000143	CcSEcCtD
Dextroamphetamine—Diarrhoea—Methotrexate—hematologic cancer	2.94e-05	0.000143	CcSEcCtD
Dextroamphetamine—Asthenia—Epirubicin—hematologic cancer	2.88e-05	0.000141	CcSEcCtD
Dextroamphetamine—Dizziness—Methotrexate—hematologic cancer	2.84e-05	0.000138	CcSEcCtD
Dextroamphetamine—Diarrhoea—Epirubicin—hematologic cancer	2.75e-05	0.000134	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Doxorubicin—hematologic cancer	2.74e-05	0.000134	CcSEcCtD
Dextroamphetamine—Vomiting—Methotrexate—hematologic cancer	2.73e-05	0.000133	CcSEcCtD
Dextroamphetamine—Rash—Methotrexate—hematologic cancer	2.71e-05	0.000132	CcSEcCtD
Dextroamphetamine—Dermatitis—Methotrexate—hematologic cancer	2.7e-05	0.000132	CcSEcCtD
Dextroamphetamine—Headache—Methotrexate—hematologic cancer	2.69e-05	0.000131	CcSEcCtD
Dextroamphetamine—Asthenia—Doxorubicin—hematologic cancer	2.67e-05	0.00013	CcSEcCtD
Dextroamphetamine—Dizziness—Epirubicin—hematologic cancer	2.66e-05	0.00013	CcSEcCtD
Dextroamphetamine—Vomiting—Epirubicin—hematologic cancer	2.55e-05	0.000125	CcSEcCtD
Dextroamphetamine—Nausea—Methotrexate—hematologic cancer	2.55e-05	0.000124	CcSEcCtD
Dextroamphetamine—Diarrhoea—Doxorubicin—hematologic cancer	2.54e-05	0.000124	CcSEcCtD
Dextroamphetamine—Rash—Epirubicin—hematologic cancer	2.53e-05	0.000124	CcSEcCtD
Dextroamphetamine—Dermatitis—Epirubicin—hematologic cancer	2.53e-05	0.000123	CcSEcCtD
Dextroamphetamine—Headache—Epirubicin—hematologic cancer	2.52e-05	0.000123	CcSEcCtD
Dextroamphetamine—Dizziness—Doxorubicin—hematologic cancer	2.46e-05	0.00012	CcSEcCtD
Dextroamphetamine—Nausea—Epirubicin—hematologic cancer	2.39e-05	0.000116	CcSEcCtD
Dextroamphetamine—Vomiting—Doxorubicin—hematologic cancer	2.36e-05	0.000115	CcSEcCtD
Dextroamphetamine—Rash—Doxorubicin—hematologic cancer	2.34e-05	0.000114	CcSEcCtD
Dextroamphetamine—Dermatitis—Doxorubicin—hematologic cancer	2.34e-05	0.000114	CcSEcCtD
Dextroamphetamine—Headache—Doxorubicin—hematologic cancer	2.33e-05	0.000114	CcSEcCtD
Dextroamphetamine—Nausea—Doxorubicin—hematologic cancer	2.21e-05	0.000108	CcSEcCtD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTHLH—hematologic cancer	8.51e-06	0.000145	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SDC1—hematologic cancer	8.51e-06	0.000145	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FBXW7—hematologic cancer	8.4e-06	0.000143	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL2RA—hematologic cancer	8.37e-06	0.000142	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTGER4—hematologic cancer	8.29e-06	0.000141	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TP53—hematologic cancer	8.28e-06	0.000141	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—LCK—hematologic cancer	8.24e-06	0.00014	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HDAC2—hematologic cancer	8.24e-06	0.00014	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CXCR4—hematologic cancer	8.24e-06	0.00014	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—IDH1—hematologic cancer	8.22e-06	0.00014	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ABCC3—hematologic cancer	8.13e-06	0.000138	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TXN—hematologic cancer	8.13e-06	0.000138	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTO1—hematologic cancer	8.13e-06	0.000138	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—H3F3A—hematologic cancer	8.08e-06	0.000137	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CBL—hematologic cancer	8.03e-06	0.000136	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SPHK1—hematologic cancer	7.96e-06	0.000135	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL3—hematologic cancer	7.95e-06	0.000135	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HRAS—hematologic cancer	7.92e-06	0.000135	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PRKCZ—hematologic cancer	7.86e-06	0.000133	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PIK3CG—hematologic cancer	7.85e-06	0.000133	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTPN1—hematologic cancer	7.81e-06	0.000133	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PTPN11—hematologic cancer	7.71e-06	0.000131	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RASGRP1—hematologic cancer	7.69e-06	0.000131	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PIK3CG—hematologic cancer	7.68e-06	0.00013	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HSP90AA1—hematologic cancer	7.66e-06	0.00013	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SYK—hematologic cancer	7.66e-06	0.00013	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—UGT1A1—hematologic cancer	7.65e-06	0.00013	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PIK3CD—hematologic cancer	7.6e-06	0.000129	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PARP1—hematologic cancer	7.59e-06	0.000129	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IL6—hematologic cancer	7.58e-06	0.000129	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CREB1—hematologic cancer	7.47e-06	0.000127	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FBXW7—hematologic cancer	7.46e-06	0.000127	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SLC22A1—hematologic cancer	7.44e-06	0.000126	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CRABP1—hematologic cancer	7.44e-06	0.000126	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—STAT1—hematologic cancer	7.39e-06	0.000126	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HDAC2—hematologic cancer	7.32e-06	0.000124	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CXCR4—hematologic cancer	7.32e-06	0.000124	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CCL2—hematologic cancer	7.31e-06	0.000124	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL6R—hematologic cancer	7.29e-06	0.000124	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ALOX5—hematologic cancer	7.25e-06	0.000123	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PIK3R1—hematologic cancer	7.18e-06	0.000122	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CBL—hematologic cancer	7.13e-06	0.000121	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL3—hematologic cancer	7.06e-06	0.00012	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NUP98—hematologic cancer	7.02e-06	0.000119	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—AKT1—hematologic cancer	7e-06	0.000119	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—JAK2—hematologic cancer	6.97e-06	0.000118	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PIK3CG—hematologic cancer	6.97e-06	0.000118	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—MAP2K1—hematologic cancer	6.95e-06	0.000118	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTPN1—hematologic cancer	6.94e-06	0.000118	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GRB2—hematologic cancer	6.91e-06	0.000117	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PIK3CD—hematologic cancer	6.9e-06	0.000117	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PDGFA—hematologic cancer	6.89e-06	0.000117	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PTPN11—hematologic cancer	6.85e-06	0.000116	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RASGRP1—hematologic cancer	6.83e-06	0.000116	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ADCY7—hematologic cancer	6.82e-06	0.000116	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NCOA3—hematologic cancer	6.82e-06	0.000116	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SYK—hematologic cancer	6.8e-06	0.000116	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HSP90AA1—hematologic cancer	6.8e-06	0.000116	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KITLG—hematologic cancer	6.8e-06	0.000115	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NUP214—hematologic cancer	6.77e-06	0.000115	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PIK3CD—hematologic cancer	6.75e-06	0.000115	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—STAT5A—hematologic cancer	6.64e-06	0.000113	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CREB1—hematologic cancer	6.64e-06	0.000113	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—MTR—hematologic cancer	6.63e-06	0.000113	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ABCG2—hematologic cancer	6.63e-06	0.000113	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PIK3CB—hematologic cancer	6.62e-06	0.000113	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CDKN2B—hematologic cancer	6.58e-06	0.000112	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—STAT1—hematologic cancer	6.56e-06	0.000111	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PIK3R1—hematologic cancer	6.52e-06	0.000111	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ENO2—hematologic cancer	6.5e-06	0.00011	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CCL2—hematologic cancer	6.49e-06	0.00011	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL6R—hematologic cancer	6.47e-06	0.00011	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PIK3R1—hematologic cancer	6.37e-06	0.000108	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CD86—hematologic cancer	6.37e-06	0.000108	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—JAK2—hematologic cancer	6.33e-06	0.000108	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTT1—hematologic cancer	6.31e-06	0.000107	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HES1—hematologic cancer	6.28e-06	0.000107	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NCOR1—hematologic cancer	6.25e-06	0.000106	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—JAK2—hematologic cancer	6.19e-06	0.000105	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CSF2—hematologic cancer	6.18e-06	0.000105	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FGF1—hematologic cancer	6.18e-06	0.000105	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—MAP2K1—hematologic cancer	6.17e-06	0.000105	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SDC1—hematologic cancer	6.16e-06	0.000105	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GRB2—hematologic cancer	6.14e-06	0.000104	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PIK3CD—hematologic cancer	6.13e-06	0.000104	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PDGFA—hematologic cancer	6.12e-06	0.000104	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FOXO1—hematologic cancer	6.09e-06	0.000103	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—IL2—hematologic cancer	6.08e-06	0.000103	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PDGFRB—hematologic cancer	6.08e-06	0.000103	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KITLG—hematologic cancer	6.04e-06	0.000103	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PIK3CB—hematologic cancer	6.02e-06	0.000102	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PDGFRA—hematologic cancer	5.98e-06	0.000102	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—JAK1—hematologic cancer	5.96e-06	0.000101	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PRKCG—hematologic cancer	5.96e-06	0.000101	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—STAT5A—hematologic cancer	5.9e-06	0.0001	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PIK3CB—hematologic cancer	5.88e-06	0.0001	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CDKN2B—hematologic cancer	5.85e-06	9.94e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PIK3R1—hematologic cancer	5.79e-06	9.83e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CD86—hematologic cancer	5.66e-06	9.61e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—JAK2—hematologic cancer	5.63e-06	9.56e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HES1—hematologic cancer	5.58e-06	9.48e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL2RA—hematologic cancer	5.57e-06	9.46e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NCOR1—hematologic cancer	5.55e-06	9.42e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL2—hematologic cancer	5.52e-06	9.39e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TERT—hematologic cancer	5.5e-06	9.35e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CSF2—hematologic cancer	5.49e-06	9.32e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FGF1—hematologic cancer	5.49e-06	9.32e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FOXO1—hematologic cancer	5.41e-06	9.18e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—IL2—hematologic cancer	5.4e-06	9.18e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PDGFRB—hematologic cancer	5.4e-06	9.17e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PDGFB—hematologic cancer	5.37e-06	9.13e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PIK3CB—hematologic cancer	5.34e-06	9.08e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PDGFRA—hematologic cancer	5.31e-06	9.03e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PRKCG—hematologic cancer	5.29e-06	8.99e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—JAK1—hematologic cancer	5.29e-06	8.99e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TSC2—hematologic cancer	5.25e-06	8.92e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CD44—hematologic cancer	5.24e-06	8.9e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NQO1—hematologic cancer	5.24e-06	8.9e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FGFR3—hematologic cancer	5.05e-06	8.58e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MAPK14—hematologic cancer	5e-06	8.5e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYCS—hematologic cancer	4.96e-06	8.42e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL2RA—hematologic cancer	4.94e-06	8.4e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	4.93e-06	8.37e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL2—hematologic cancer	4.91e-06	8.34e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ESR1—hematologic cancer	4.91e-06	8.33e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TERT—hematologic cancer	4.89e-06	8.31e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FN1—hematologic cancer	4.85e-06	8.23e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—BAD—hematologic cancer	4.79e-06	8.13e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NFKBIA—hematologic cancer	4.79e-06	8.13e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PDGFB—hematologic cancer	4.77e-06	8.11e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NOTCH1—hematologic cancer	4.74e-06	8.06e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TSC2—hematologic cancer	4.66e-06	7.92e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CD80—hematologic cancer	4.65e-06	7.89e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KIT—hematologic cancer	4.64e-06	7.88e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PIK3CG—hematologic cancer	4.64e-06	7.88e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—NRAS—hematologic cancer	4.64e-06	7.88e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTPN11—hematologic cancer	4.56e-06	7.74e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FGFR3—hematologic cancer	4.49e-06	7.62e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MAPK14—hematologic cancer	4.44e-06	7.55e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—MAPK3—hematologic cancer	4.44e-06	7.55e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CREB1—hematologic cancer	4.41e-06	7.5e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTP1—hematologic cancer	4.37e-06	7.43e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—BRAF—hematologic cancer	4.36e-06	7.41e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ESR1—hematologic cancer	4.36e-06	7.4e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCL2—hematologic cancer	4.32e-06	7.34e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL6R—hematologic cancer	4.31e-06	7.32e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FN1—hematologic cancer	4.3e-06	7.31e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CREBBP—hematologic cancer	4.3e-06	7.3e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NFKBIA—hematologic cancer	4.25e-06	7.23e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—BAD—hematologic cancer	4.25e-06	7.23e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NOTCH1—hematologic cancer	4.21e-06	7.16e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ABCB1—hematologic cancer	4.14e-06	7.03e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CD80—hematologic cancer	4.13e-06	7.01e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PIK3CG—hematologic cancer	4.12e-06	7e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KIT—hematologic cancer	4.12e-06	7e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—NRAS—hematologic cancer	4.12e-06	7e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MAP2K1—hematologic cancer	4.1e-06	6.97e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PIK3CD—hematologic cancer	4.08e-06	6.93e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTPN11—hematologic cancer	4.05e-06	6.88e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PIK3CA—hematologic cancer	4.04e-06	6.86e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTM1—hematologic cancer	4.02e-06	6.82e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NCOR1—hematologic cancer	4.02e-06	6.82e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—KRAS—hematologic cancer	3.99e-06	6.78e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—MAPK3—hematologic cancer	3.94e-06	6.7e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CREB1—hematologic cancer	3.92e-06	6.66e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FGF2—hematologic cancer	3.9e-06	6.63e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—BRAF—hematologic cancer	3.87e-06	6.58e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PIK3R1—hematologic cancer	3.85e-06	6.54e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCL2—hematologic cancer	3.84e-06	6.52e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL6R—hematologic cancer	3.82e-06	6.5e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CREBBP—hematologic cancer	3.82e-06	6.49e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—JAK2—hematologic cancer	3.74e-06	6.36e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PIK3CA—hematologic cancer	3.67e-06	6.23e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MDM2—hematologic cancer	3.65e-06	6.2e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MAP2K1—hematologic cancer	3.65e-06	6.19e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PIK3CD—hematologic cancer	3.62e-06	6.15e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PIK3CA—hematologic cancer	3.59e-06	6.09e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PIK3CB—hematologic cancer	3.55e-06	6.04e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MTOR—hematologic cancer	3.55e-06	6.04e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—MTHFR—hematologic cancer	3.55e-06	6.03e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—KRAS—hematologic cancer	3.55e-06	6.02e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FGF2—hematologic cancer	3.47e-06	5.89e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PIK3R1—hematologic cancer	3.42e-06	5.81e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—HRAS—hematologic cancer	3.39e-06	5.76e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CDKN1B—hematologic cancer	3.33e-06	5.67e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—JAK2—hematologic cancer	3.32e-06	5.65e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—AKT1—hematologic cancer	3.3e-06	5.6e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CASP3—hematologic cancer	3.27e-06	5.55e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL2—hematologic cancer	3.26e-06	5.54e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PIK3CA—hematologic cancer	3.26e-06	5.53e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL6—hematologic cancer	3.25e-06	5.52e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MDM2—hematologic cancer	3.24e-06	5.51e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCND1—hematologic cancer	3.18e-06	5.4e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—JUN—hematologic cancer	3.17e-06	5.39e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MTOR—hematologic cancer	3.16e-06	5.36e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PIK3CB—hematologic cancer	3.16e-06	5.36e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CDKN1A—hematologic cancer	3.08e-06	5.23e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTEN—hematologic cancer	3.07e-06	5.22e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	3.01e-06	5.12e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MAPK8—hematologic cancer	3e-06	5.1e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—AKT1—hematologic cancer	3e-06	5.09e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PIK3CG—hematologic cancer	2.98e-06	5.07e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	2.96e-06	5.03e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	2.93e-06	4.98e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—EP300—hematologic cancer	2.93e-06	4.97e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	2.9e-06	4.93e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL2—hematologic cancer	2.9e-06	4.92e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	2.88e-06	4.9e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SRC—hematologic cancer	2.85e-06	4.84e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	2.83e-06	4.8e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—JUN—hematologic cancer	2.82e-06	4.79e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	2.77e-06	4.71e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CREBBP—hematologic cancer	2.77e-06	4.7e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	2.75e-06	4.67e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	2.74e-06	4.65e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	2.73e-06	4.64e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	2.73e-06	4.63e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	2.67e-06	4.53e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	2.66e-06	4.52e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	2.62e-06	4.46e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	2.62e-06	4.45e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—EP300—hematologic cancer	2.6e-06	4.42e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ALB—hematologic cancer	2.59e-06	4.4e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MYC—hematologic cancer	2.55e-06	4.34e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	2.55e-06	4.32e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SRC—hematologic cancer	2.53e-06	4.3e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.48e-06	4.21e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	2.46e-06	4.19e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	2.44e-06	4.14e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	2.43e-06	4.13e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	2.36e-06	4.01e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	2.33e-06	3.96e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.29e-06	3.88e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MYC—hematologic cancer	2.27e-06	3.85e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	2.26e-06	3.84e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	2.17e-06	3.68e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TP53—hematologic cancer	2.1e-06	3.56e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	2.09e-06	3.56e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	2e-06	3.4e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PTEN—hematologic cancer	1.97e-06	3.36e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	1.92e-06	3.27e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL6—hematologic cancer	1.92e-06	3.26e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—EP300—hematologic cancer	1.88e-06	3.2e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TP53—hematologic cancer	1.86e-06	3.16e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	1.78e-06	3.02e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	1.77e-06	3.01e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL6—hematologic cancer	1.7e-06	2.89e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	1.57e-06	2.67e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.39e-06	2.37e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—AKT1—hematologic cancer	1.14e-06	1.93e-05	CbGpPWpGaD
